Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
03/21/2017 03/22/2017 03/23/2017 03/24/2017 03/27/2017 Date
71.446(c) 69.9(c) 69.089(c) 70.795(c) 70.42 Last
0 23 0 2 443 0 Volume
-0.76% -2.16% -1.16% +2.47% -0.53% Change
More quotes
Financials (€)
Sales 2017 4 305 M
EBIT 2017 926 M
Net income 2017 615 M
Debt 2017 596 M
Yield 2017 1,77%
Sales 2018 4 517 M
EBIT 2018 1 090 M
Net income 2018 727 M
Finance 2018 43,5 M
Yield 2018 1,79%
P/E ratio 2017 20,78
P/E ratio 2018 17,45
EV / Sales2017 3,34x
EV / Sales2018 3,04x
Capitalization 13 771 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
04/24Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
03/24 UCB : General Meeting on 27 April 27 2017
03/24 UCB : Convening notice to attend the general meeting of shareholders
03/23 UCB : U.S. Patent and Trademark Office confirms validity of patent …
03/17 UCB : Brussels - Transparency notifications
03/16 UCB : Transparency notifications
03/10 UCB : Acquisition of own shares
03/09 UCB : Researchers from UCB S.A. Report New Studies and Findings in the Area of E..
03/09 UCB : Transparency notification
03/09 SCHEDULES OF CONTROLLED SUBSTANCES : Placement of Brivaracetam Into Schedule V
03/08 UCB : Transparency notification
More news
Sector news : Pharmaceuticals - NEC
08:03pDJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
05:37pDJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
04:16pDJEU Clears Dow-DuPont Deal With Conditions -- Update
09:25a Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 76,9 €
Spread / Average Target 8,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA15.35%14 866
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results